奥马珠单抗对过敏性哮喘患者炎症标记物的影响
2009/12/15
哮喘是一种气道慢性炎症性疾病，免疫球蛋白E（IgE）通过与FcepsilonRI和FcepsilonRII受体结合活化一系列炎症细胞而在哮喘的发病过程中起到重要作用。IgE在过敏性炎症中的作用为针对中度或重度过敏性哮喘患者开发奥马珠单抗（一种人化的抗IgE奥马珠抗体）提供了理论基础。奥马珠单抗治疗后可引起循环IgE水平下降，从而使FcepsilonRI 受体在肥大细胞、嗜碱性粒细胞和树突状细胞中的表达下降。
上述联合效果可导致一些炎症标记物的下降，其中包括外周和支气管组织中的嗜酸性粒细胞、粒细胞巨噬细胞集落刺激因子、IL2、IL-4、IL-5和IL-13。通过阻断IgE与受体的结合及抑制树突状细胞FcepsilonRI受体表达，奥马珠单抗也能减少提呈给T细胞的抗原量及降低Th2细胞因子的产生。奥马珠单抗的抗炎作用可能能解释为什么中度或重度、持续性、控制不佳的过敏性哮喘患者在使用奥马珠单抗后能减少哮喘恶化和哮喘症状。
（陈欣 审校）
Allergy. 2009 Oct 15. [Epub ahead of print]
Effects of omalizumab on markers of inflammation in patients with allergic asthma.
Holgate S, Smith N, Massanari M, Jimenez P.
Southampton General Hospital, Southampton.
Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE) plays a key role by activating a variety of inflammatory cells through interactions with FcepsilonRI and FcepsilonRII receptors. The role of IgE in allergic inflammation provided the rationale for developing omalizumab, a humanized monoclonal anti-IgE antibody, for patients with moderate-to-severe or severe allergic asthma. The reductions in circulating levels of IgE resulting from omalizumab treatment leads to reductions in FcepsilonRI expression on mast cells, basophils and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony stimulating factor, interleukin (IL)-2, IL-4, IL-5 and IL-13. By blocking IgE binding to its receptors and diminishing dendritic cell FcepsilonRI receptor expression, omalizumab may also reduce allergen presentation to T cells and the production of Th2 cytokines. The anti-inflammatory effects of omalizumab may, therefore, explain the reductions in asthma exacerbations and symptoms seen in clinical trials in patients with moderate-to-severe or severe, persistent, inadequately controlled allergic asthma.
Allergy. 2009 Oct 15. [Epub ahead of print]
上述联合效果可导致一些炎症标记物的下降，其中包括外周和支气管组织中的嗜酸性粒细胞、粒细胞巨噬细胞集落刺激因子、IL2、IL-4、IL-5和IL-13。通过阻断IgE与受体的结合及抑制树突状细胞FcepsilonRI受体表达，奥马珠单抗也能减少提呈给T细胞的抗原量及降低Th2细胞因子的产生。奥马珠单抗的抗炎作用可能能解释为什么中度或重度、持续性、控制不佳的过敏性哮喘患者在使用奥马珠单抗后能减少哮喘恶化和哮喘症状。
（陈欣 审校）
Allergy. 2009 Oct 15. [Epub ahead of print]
Effects of omalizumab on markers of inflammation in patients with allergic asthma.
Holgate S, Smith N, Massanari M, Jimenez P.
Southampton General Hospital, Southampton.
Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE) plays a key role by activating a variety of inflammatory cells through interactions with FcepsilonRI and FcepsilonRII receptors. The role of IgE in allergic inflammation provided the rationale for developing omalizumab, a humanized monoclonal anti-IgE antibody, for patients with moderate-to-severe or severe allergic asthma. The reductions in circulating levels of IgE resulting from omalizumab treatment leads to reductions in FcepsilonRI expression on mast cells, basophils and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony stimulating factor, interleukin (IL)-2, IL-4, IL-5 and IL-13. By blocking IgE binding to its receptors and diminishing dendritic cell FcepsilonRI receptor expression, omalizumab may also reduce allergen presentation to T cells and the production of Th2 cytokines. The anti-inflammatory effects of omalizumab may, therefore, explain the reductions in asthma exacerbations and symptoms seen in clinical trials in patients with moderate-to-severe or severe, persistent, inadequately controlled allergic asthma.
Allergy. 2009 Oct 15. [Epub ahead of print]
上一篇：
喘息住院婴儿嗜酸性粒细胞活性和儿童持续性哮喘风险
下一篇：
过敏性哮喘患者中的Th17免疫
